Is Desmopressin FDA approved?

Desmopressin is FDA approved (FDA status current as of 1978-01-01). This regulatory status is provided for research and educational context only.

How is Desmopressin administered in research settings?

In research settings, Desmopressin is typically administered via the intranasal, oral, or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is DSIP administered in research settings?

In research settings, DSIP is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Desmopressin vs DSIP

Peptide Comparison

Desmopressin vs DSIP

Name: Desmopressin vs DSIP — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Neuro & Cognitive peptides.

Desmopressin

DDAVP

CognitiveFDA ApprovedPrescription

Half-life: 1.5-2.5 hours (intranasal)

2 providers listed

Full Desmopressin profile →

DSIP

Delta Sleep-Inducing Peptide

RecoveryResearch Only

Half-life: 30–60 minutes

94 providers listed

Full DSIP profile →

Bottom line

Desmopressin is FDA-approved, while DSIP is nomination withdrawn — the clearest structural difference between them.

Quick Verdict

Desmopressin

Evidence

Clinical

Half-life

1.5-2.5 hours (intranasal)

DSIP

Evidence

Preclinical

Half-life

30–60 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Desmopressin
Further along in FDA review	Desmopressin
Less frequent dosing (longer half-life)	Desmopressin
Oral administration option	Desmopressin
More provider options (2 vs 94)	DSIP

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Desmopressin

DSIP

Mechanism Family

Neuro & Cognitive

Half-life

1.5-2.5 hours (intranasal)

30–60 minutes

FDA Status

approved

nomination withdrawn

Admin Routes

intranasal, oral, subcutaneous

subcutaneous, intranasal

Availability

Prescription

Research Only

Providers

2 listed

94 listed

FDA Update

Jan 1978

—

Avail. Notes

FDA-approved synthetic vasopressin analog. Brands: DDAVP (NDA 017922), Stimate, Nocdurna (NDA 201532, Jun 2018). Approved forms: injection, intranasal, oral, sublingual. Prescription only.

Endogenous neuropeptide discovered 1977. Studied for sleep disorders but no FDA approval, no NDA or IND. Not on 503A bulks list. Sold as research chemical only.

Research Evidence

Desmopressin

ClinicalRCT · 7 key studies · most recent 2026

DSIP

PreclinicalAnimal · 1 key study · dated evidence base — most recent 1979

Research Citations

Desmopressin

Cohort2026 · BMC Nephrol

Proactive desmopressin for the prevention of serum sodium overcorrection in moderate-to-severe hyponatremia:…

Cohort2026 · Clinical Endocrinology

Clinical Outcomes Following Supply-Driven Transition From Intranasal to Oral Desmopressin in AVP-Deficiency

Cohort2026 · Int J Urol

Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population-Based Analysis (2…

Cohort2026 · J Pediatr Hematol Oncol

Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.

+3 more

DSIP

Animal1979 · Neuroscience Letters

The delta-sleep inducing peptide (DSIP) increases duration of sleep in rats

About Desmopressin

Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

Research Areas

memory consolidationlearning enhancementantidiuretichemostasis

About DSIP

Neuropeptide that modulates sleep architecture by promoting delta-wave sleep patterns. Reduces stress hormones including ACTH and cortisol, and interacts with hypothalamic-pituitary pathways to support recovery and circadian regulation.

Research Areas

sleep qualitystress reductionrecoverycortisol regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Desmopressin

Reported (Unverified — Pending Clinical Review)

hyponatremiaheart failureuncontrolled hypertensionpsychogenic polydipsia

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

DSIP

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Desmopressin

Not enough vendor pricing yet.

DSIP

$5.05/mg

$4.22 – $8.85 range

22 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Desmopressin

2 listed

Browse directory →

Providers offering

DSIP

94 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 22, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Desmopressin vs DSIP — Per-mg Price Comparison. Retrieved July 23, 2026, from https://peptidebase.io/peptides/compare/desmopressin/dsip

https://peptidebase.io/peptides/compare/desmopressin/dsip Methodology License Download JSON Download CSV